argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

argenx SE

argenx focuses on innovating immunology solutions to reach patients.

	Mar '14	Jun '14	Mar '21	Jun '21	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24
net income	-2.61M -	-3.73M 43.16%	-34.49M 823.42%	87.36M 353.29%	-201.70M 330.89%	-208.95M 3.59%	-205.35M 1.72%	-199.25M 2.97%	-239.86M 20.38%	-36.06M 84.96%	-26.62M 26.20%	-86.48M 224.91%	-68.71M 20.54%	-89.83M 30.73%	-57.08M 36.46%	29.07M 150.92%
depreciation and amortization	27.51K -	31.16K 13.28%
deferred income tax
stock based compensation	38.51K -	466.28K 1,110.83%			-79.48M -	157.59M 298.28%				146.65M -				211.03M -		102.38M -
change in working capital	-673.91K -	3.55M 626.55%
accounts receivables
inventory
accounts payables
other working capital	-673.91K -	3.55M 626.55%
other non cash items	-0.00 -	0.00 112.50%	34.49M 59,252,250,406,132,121,600%	-87.36M 353.29%	281.18M 421.87%	51.36M 81.74%	205.35M 299.86%	199.25M 2.97%	239.86M 20.38%	36.06M 84.96%	26.62M 26.20%	86.48M 224.91%	68.71M 20.54%	-121.20M 276.39%	57.08M 147.10%	-131.45M 330.28%
net cash provided by operating activities	-3.22M -	310.94K 109.67%								146.65M -
investments in property plant and equipment	-1.38K -	-42.28K 2,974.33%
acquisitions net
purchases of investments
sales maturities of investments
other investing activites	48.14K -	40.54K 15.78%
net cash used for investing activites	46.76K -	-1.74K 103.72%
debt repayment
common stock issued
common stock repurchased
dividends paid
other financing activites
net cash used provided by financing activities		-249.30K -
effect of forex changes on cash		20.46K -
net change in cash	-3.17M -	80.36K 102.54%								146.65M -
cash at beginning of period	31.25M -	28.08M 10.15%
cash at end of period	28.08M -	28.16M 0.29%								146.65M -
operating cash flow	-3.22M -	310.94K 109.67%								146.65M -
capital expenditure	-1.38K -	-42.28K 2,974.33%
free cash flow	-3.22M -	268.66K 108.35%								146.65M -

COM:ARGENX

argenx

Last Close

564.80

22/11 16:39

Market Cap

25.12B

Beta: -

Volume Today

74.86K

Avg: -

Preview